97 results
8-K
EX-10.1
CRVS
Corvus Pharmaceuticals Inc
6 May 24
Entry into a Material Definitive Agreement
4:11pm
, occupational health and safety, product quality and safety and employment and labor matters, except in each case as would not have or reasonably
8-K
EX-99.1
CRVS
Corvus Pharmaceuticals Inc
6 May 24
Corvus Pharmaceuticals Provides Business Update and Reports First Quarter 2024 Financial Results
4:01pm
group. The endpoints include safety and improvement in Eczema Area and Severity Index. Patients and physicians will be blinded to treatment assignment … -looking statements, including statements related to the potential safety and efficacy of the Company’s product candidates including soquelitinib
424B5
CRVS
Corvus Pharmaceuticals Inc
3 May 24
Prospectus supplement for primary offering
4:05pm
to provide greater safety compared to other cancer therapies and may facilitate their development either as monotherapies or in combination with other
8-K
EX-99.1
dwdj1 g4lt
19 Mar 24
Corvus Pharmaceuticals Provides Business Update and Reports Fourth Quarter and Full Year 2023 Financial Results
4:02pm
8-K
EX-99.1
pkz5a2 h9v
7 Nov 23
Corvus Pharmaceuticals Provides Business Update and Reports Third Quarter 2023 Financial Results
4:03pm
8-K
EX-99.1
rd1ame8cqq9y8r
6 Sep 23
Other Events
7:39pm
8-K
EX-99.1
vkkq 017hrz
8 Aug 23
Corvus Pharmaceuticals Provides Business Update and Reports Second Quarter 2023 Financial Results
4:01pm
8-K
EX-99.1
t3922m8o
8 May 23
Corvus Pharmaceuticals Provides Business Update and Reports First Quarter 2023 Financial Results
4:01pm
8-K
EX-99.1
1m5i5cnc1u
3 Nov 22
Corvus Pharmaceuticals Provides Business Update and Reports Third Quarter 2022 Financial Results
4:06pm
8-K
EX-99.1
ebksc7 ugt93roq3p9n2
8 Aug 22
Corvus Pharmaceuticals Provides Business Update and Reports Second Quarter 2022 Financial Results
4:05pm
8-K
EX-99.1
rf2f4z6p qlkn3
5 May 22
Corvus Pharmaceuticals Provides Business Update and Reports First Quarter 2022 Financial Results
12:00am